Convert your VIP dose
Vial
Result
Converted amount0.25 mg
Dose mass250 mcg
Concentration2,500 mcg/mL
Draw volume0.1 mL
U-100 syringe10 units
Reported study ranges
| Purpose | Route | Reported range | Frequency |
|---|---|---|---|
| COVID-19 respiratory failure (clinical trial protocol) | intravenous | 0.166–0.498 mcg/kg/hr | escalating over 3 days |
Ranges are reported from the literature for research context only. They are not a protocol and not a recommendation. 1 further range is recorded on the profile but withheld here because no published study established it.
Concentration by vial and diluent
| Vial | 1 mL diluent | 2 mL diluent | 3 mL diluent |
|---|---|---|---|
| 2 mg | 2,000 mcg/mL | 1,000 mcg/mL | 667 mcg/mL |
| 5 mg | 5,000 mcg/mL | 2,500 mcg/mL | 1,667 mcg/mL |
| 10 mg | 10,000 mcg/mL | 5,000 mcg/mL | 3,333 mcg/mL |
Concentration is vial mass divided by diluent volume. Reconstitution volume changes what you draw, never the dose itself.
VIP at a glance
~2 minutes (IV); nasal absorption highly variable
Half-life
3,326.8 Da
Molecular weight
intravenous, nasal
Routes
research only
Legal status